JP2014156496A5 - 生分解性眼内インプラント - Google Patents
生分解性眼内インプラント Download PDFInfo
- Publication number
- JP2014156496A5 JP2014156496A5 JP2014114968A JP2014114968A JP2014156496A5 JP 2014156496 A5 JP2014156496 A5 JP 2014156496A5 JP 2014114968 A JP2014114968 A JP 2014114968A JP 2014114968 A JP2014114968 A JP 2014114968A JP 2014156496 A5 JP2014156496 A5 JP 2014156496A5
- Authority
- JP
- Japan
- Prior art keywords
- implant
- eye
- kinase inhibitor
- biodegradable intraocular
- tyrosine kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
本発明は、インプラントを配置した眼に治療薬の長時間放出を与える、チロシンキナーゼインヒビターおよび生分解性ポリマーを含む生分解性眼内インプラントに関する。
本発明は、チロシンキナーゼインヒビターおよびポリ（ラクチド−コ−グリコリド）を含んでなる眼に配置するための生分解性眼内インプラントであって、チロシンキナーゼインヒビターはインプラントの３０〜６０重量％の量で存在し、チロシンキナーゼインヒビターはインプラントが眼に移植された後少なくとも１４日間にわたって線形放出プロフィールでインプラントから放出され、インプラントは放出制御剤およびポリビニルアルコールを含有せず、チロシンキナーゼインヒビターは押出によりポリ（ラクチド−コ−グリコリド）に配合され、インプラントはロッドまたは微小球の形状である、生分解性眼内インプラントを提供する。
本発明の１つの好ましい態様では、ポリ（ラクチド−コ−グリコリド）中のラクチド対グリコリドの比は、５０：５０または７５：２５である。
本発明の別の好ましい態様では、インプラントは、眼の硝子体、眼の結膜下腔または眼の脈絡膜上腔に配置される。
本発明の更に別の好ましい態様では、チロシンキナーゼインヒビターはインプラント全体に均一に分布されている。
本発明の別の好ましい態様では、インプラントは、眼の硝子体、眼の結膜下腔または眼の脈絡膜上腔に配置される。
本発明の更に別の好ましい態様では、チロシンキナーゼインヒビターはインプラント全体に均一に分布されている。
本発明の生分解性眼内インプラントを眼に配置された患者は、薬剤の付加的投与を必要とせずに、長期間または延長された期間にわたって、治療量の薬剤を受ける。例えば、患者は、比較的長い期間にわたって、例えば、インプラントを配置されてから、少なくとも14日間にわたって、実質的に一貫したレベルの治療的活性剤を、一貫した眼の治療のために得ることができる。そのような長い放出時間は、優れた治療効果を得ることを促進する。このインプラントは、侵襲的手段を減らし、断続的な投与に伴う高い一時的な濃度を減少しつつ、治療薬の送達時間を延長することができる。
Claims (4)
- チロシンキナーゼインヒビターおよびポリ（ラクチド−コ−グリコリド）を含んでなる眼に配置するための生分解性眼内インプラントであって、チロシンキナーゼインヒビターはインプラントの３０〜６０重量％の量で存在し、チロシンキナーゼインヒビターはインプラントが眼に移植された後少なくとも１４日間にわたって線形放出プロフィールでインプラントから放出され、インプラントは放出制御剤およびポリビニルアルコールを含有せず、チロシンキナーゼインヒビターは押出によりポリ（ラクチド−コ−グリコリド）に配合され、インプラントはロッドまたは微小球の形状である、生分解性眼内インプラント。
- ポリ（ラクチド−コ−グリコリド）中のラクチド対グリコリドの比は、５０：５０または７５：２５である、請求項１に記載の生分解性眼内インプラント。
- インプラントは、眼の硝子体、眼の結膜下腔または眼の脈絡膜上腔に配置される請求項１に記載の生分解性眼内インプラント。
- チロシンキナーゼインヒビターはインプラント全体に均一に分布されている請求項１に記載の生分解性眼内インプラント。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/837,361 US7771742B2 (en) | 2004-04-30 | 2004-04-30 | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US10/837,361 | 2004-04-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012003321A Division JP5586637B2 (ja) | 2004-04-30 | 2012-01-11 | 生分解性活性薬剤微小球の製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014156496A JP2014156496A (ja) | 2014-08-28 |
| JP2014156496A5 true JP2014156496A5 (ja) | 2014-10-09 |
| JP5985536B2 JP5985536B2 (ja) | 2016-09-06 |
Family
ID=34967821
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511016A Pending JP2007535556A (ja) | 2004-04-30 | 2005-04-27 | チロシンキナーゼインヒビターおよび生分解性ポリマーをカプセル化する微小球を含む硝子体内インプラント |
| JP2007511075A Active JP5582680B2 (ja) | 2004-04-30 | 2005-04-29 | 生分解性チロシンキナーゼインヒビター硝子体内インプラント |
| JP2011178804A Active JP5608138B2 (ja) | 2004-04-30 | 2011-08-18 | 生分解性チロシンキナーゼインヒビター硝子体内インプラント |
| JP2012003321A Active JP5586637B2 (ja) | 2004-04-30 | 2012-01-11 | 生分解性活性薬剤微小球の製造方法 |
| JP2014114968A Active JP5985536B2 (ja) | 2004-04-30 | 2014-06-03 | 生分解性眼内インプラント |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511016A Pending JP2007535556A (ja) | 2004-04-30 | 2005-04-27 | チロシンキナーゼインヒビターおよび生分解性ポリマーをカプセル化する微小球を含む硝子体内インプラント |
| JP2007511075A Active JP5582680B2 (ja) | 2004-04-30 | 2005-04-29 | 生分解性チロシンキナーゼインヒビター硝子体内インプラント |
| JP2011178804A Active JP5608138B2 (ja) | 2004-04-30 | 2011-08-18 | 生分解性チロシンキナーゼインヒビター硝子体内インプラント |
| JP2012003321A Active JP5586637B2 (ja) | 2004-04-30 | 2012-01-11 | 生分解性活性薬剤微小球の製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US7771742B2 (ja) |
| EP (2) | EP1742610B1 (ja) |
| JP (5) | JP2007535556A (ja) |
| AU (2) | AU2005244780B2 (ja) |
| BR (1) | BRPI0509461A (ja) |
| CA (2) | CA2565182C (ja) |
| WO (2) | WO2005107706A2 (ja) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060177416A1 (en) | 2003-10-14 | 2006-08-10 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| AU2003228427B2 (en) * | 2002-04-03 | 2009-07-02 | Allergan, Inc. | (3Z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| JP2007518804A (ja) | 2004-01-20 | 2007-07-12 | アラーガン、インコーポレイテッド | トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物 |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| JP2008535847A (ja) * | 2005-04-08 | 2008-09-04 | サーモディクス，インコーポレイティド | 網膜下に送達するための持続放出インプラント |
| EP1933881B1 (en) | 2005-09-22 | 2019-03-13 | Medivas, LLC | Solid polymer delivery compositions and methods for use thereof |
| US8445007B2 (en) | 2005-09-22 | 2013-05-21 | Medivas, Llc | Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use |
| NZ571300A (en) | 2006-04-07 | 2011-12-22 | Warner Chilcott Co Llc | Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof |
| US20070292476A1 (en) * | 2006-05-02 | 2007-12-20 | Medivas, Llc | Delivery of ophthalmologic agents to the exterior or interior of the eye |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20090304576A1 (en) * | 2006-08-08 | 2009-12-10 | Warren Stephen L | Device for delivery of anti-cancer agents to tissue |
| EP2409687B1 (en) * | 2006-11-09 | 2014-06-11 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US8492334B2 (en) | 2007-06-21 | 2013-07-23 | Yale University | Sustained intraocular delivery of drugs from biodegradable polymeric microparticles |
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| WO2009140246A2 (en) | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| EP2296621A1 (en) * | 2008-05-20 | 2011-03-23 | Yale University | Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use |
| US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| US20100278897A1 (en) * | 2009-05-01 | 2010-11-04 | Allergan, Inc. | Intraocular bioactive agent delivery system with molecular partitioning system |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
| DK2451279T3 (da) | 2009-07-06 | 2019-05-20 | Aerpio Therapeutics Inc | Benzosulfonamid derivater forbindelser deraf og deres brug til at forhindre metastaser af cancerceller |
| US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
| KR20180117211A (ko) * | 2010-01-22 | 2018-10-26 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT |
| WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| US8349005B2 (en) | 2011-01-03 | 2013-01-08 | Masatoshi Murata | Method for burying implant to choroid |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| PT2717914T (pt) * | 2011-06-10 | 2019-12-18 | Ramscor Inc | Formulações de libertação sustentada para administração de proteínas ao olho e métodos de preparação das mesmas |
| US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
| EP3159368B1 (en) | 2011-06-23 | 2024-07-24 | DSM IP Assets B.V. | New biodegradable polyesteramide copolymers for drug delivery |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| WO2013110028A1 (en) | 2012-01-19 | 2013-07-25 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| US9388176B2 (en) | 2012-03-12 | 2016-07-12 | Allergan, Inc. | Method of treating conditiions with kinase inhibitors |
| WO2013138396A1 (en) | 2012-03-12 | 2013-09-19 | Allergan, Inc. | Dihydropyridopyrimidine and dihydronaphthyridine derivatives as tyrosine kinase inhibitors of especially vegf and pdgf |
| CN104394891B (zh) | 2012-03-16 | 2019-04-16 | 约翰霍普金斯大学 | 用于递送活性剂的非线性多嵌段共聚物-药物结合物 |
| CA2867381C (en) | 2012-03-16 | 2016-09-20 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| CA2871745C (en) | 2012-05-03 | 2023-01-24 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| JP6360039B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| CA2872519C (en) | 2012-05-04 | 2017-09-05 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| EP2964194B1 (en) | 2013-03-05 | 2022-08-17 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery |
| US20140271772A1 (en) * | 2013-03-15 | 2014-09-18 | Barry J. Margulies | Biodegradable subcutaneous implants and methods of making |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| CA2936239A1 (en) | 2014-01-16 | 2015-07-23 | Ontogenesis, Llc | Compositions and methods for the treatment of intraocular neovascularization and/or leakage |
| WO2015127368A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic microbicidal formulations and methods of use |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| EP4445952A2 (en) * | 2014-12-15 | 2024-10-16 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of glaucoma |
| CN107106509B (zh) | 2014-12-18 | 2021-11-30 | 帝斯曼知识产权资产管理有限公司 | 用于递送酸敏感药物的药物递送系统 |
| US10485757B2 (en) | 2015-01-27 | 2019-11-26 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| CA2986692A1 (en) * | 2015-05-29 | 2016-12-08 | Edge Therapeutics, Inc. | Compositions and methods for reducing visual loss |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| EP3352749A4 (en) | 2015-09-22 | 2019-09-04 | Graybug Vision, Inc. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS |
| CN108290057A (zh) | 2015-09-23 | 2018-07-17 | 爱尔皮奥治疗有限公司 | 用tie-2的激活剂治疗眼内压的方法 |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| AU2016353355B9 (en) | 2015-11-12 | 2022-09-29 | Graybug Vision, Inc. | Aggregating microparticles for therapy |
| CN109937025B (zh) | 2016-04-20 | 2022-07-29 | 多斯医学公司 | 生物可吸收眼部药物的递送装置 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| US20170342383A1 (en) | 2016-05-27 | 2017-11-30 | Corning Incorporated | Lithium disilicate glass-ceramic compositions and methods thereof |
| US10751367B2 (en) | 2016-05-27 | 2020-08-25 | Corning Incorporated | Bioactive glass microspheres |
| US10647962B2 (en) | 2016-05-27 | 2020-05-12 | Corning Incorporated | Bioactive aluminoborate glasses |
| US10676713B2 (en) | 2016-05-27 | 2020-06-09 | Corning Incorporated | Bioactive borophosphate glasses |
| US10059621B2 (en) | 2016-05-27 | 2018-08-28 | Corning Incorporated | Magnetizable glass ceramic composition and methods thereof |
| US11395853B2 (en) | 2016-06-23 | 2022-07-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions |
| EP3448389B1 (en) | 2016-06-27 | 2021-09-29 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
| CA3028751A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| IL294069B2 (en) | 2017-03-01 | 2023-11-01 | Achillion Pharmaceuticals Inc | Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders |
| RU2019133337A (ru) | 2017-03-23 | 2021-04-23 | Грейбуг Вижн, Инк. | Лекарственные средства и композиции для лечения глазных нарушений |
| MX2019013363A (es) | 2017-05-10 | 2020-01-13 | Graybug Vision Inc | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. |
| IL271399B (en) | 2017-06-20 | 2022-07-01 | Leo Pharma As | Methods for the preparation of heterocyclic 3,1-benzodioxole compounds |
| US11253480B2 (en) | 2017-10-30 | 2022-02-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor |
| EP3717426A1 (en) | 2017-11-28 | 2020-10-07 | Corning Incorporated | Chemically strengthened bioactive glass-ceramics |
| CN111417603B (zh) | 2017-11-28 | 2023-10-31 | 康宁股份有限公司 | 生物活性硼酸盐玻璃及其方法 |
| EP3717030A1 (en) | 2017-11-28 | 2020-10-07 | Corning Incorporated | Bioactive glass compositions and dentin hypersensitivity remediation |
| EP3717427A1 (en) | 2017-11-28 | 2020-10-07 | Corning Incorporated | High liquidus viscosity bioactive glass |
| EP3724196B9 (en) | 2017-12-15 | 2023-03-22 | UNION therapeutics A/S | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors |
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| WO2020041301A1 (en) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
| WO2020223209A1 (en) | 2019-04-29 | 2020-11-05 | Aerpio Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| WO2020243608A1 (en) | 2019-05-31 | 2020-12-03 | Dose Medical Corporation | Bioerodible polyester polymer implants and related methods of use |
| BR112021026265A2 (pt) | 2019-06-27 | 2022-06-14 | Layerbio Inc | Métodos e sistemas de entrega de dispositivos oculares |
| WO2021178920A1 (en) | 2020-03-05 | 2021-09-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of brd9 |
| WO2021237096A1 (en) * | 2020-05-21 | 2021-11-25 | Graybug Vision, Inc. | Durable implants and microparticles for long-term ocular therapy |
| CN111861124B (zh) * | 2020-06-18 | 2023-07-25 | 汕头大学 | 适用于注塑机的可识别性能评估方法、系统及存储介质 |
| WO2022040130A1 (en) * | 2020-08-18 | 2022-02-24 | Oakwood Laboratories, Llc | Microsphere formulations comprising ketamine and methods for making and using the same |
| JP2023546112A (ja) | 2020-10-15 | 2023-11-01 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 長時間作用型眼送達用非共有結合タンパク質－ヒアルロナンコンジュゲート |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| SE390255B (sv) * | 1974-02-18 | 1976-12-13 | N G Y Torphammar | Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon |
| GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US3966749A (en) * | 1975-02-10 | 1976-06-29 | Interx Research Corporation | Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof |
| US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
| US4052505A (en) * | 1975-05-30 | 1977-10-04 | Alza Corporation | Ocular therapeutic system manufactured from copolymer |
| US4057619A (en) | 1975-06-30 | 1977-11-08 | Alza Corporation | Ocular therapeutic system with selected membranes for administering ophthalmic drug |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4186184A (en) * | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| US4190642A (en) * | 1978-04-17 | 1980-02-26 | Alza Corporation | Ocular therapeutic system for dispensing a medication formulation |
| US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4303637A (en) | 1980-04-04 | 1981-12-01 | Alza Corporation | Medication indicated for ocular hypertension |
| US4281654A (en) * | 1980-04-07 | 1981-08-04 | Alza Corporation | Drug delivery system for controlled ocular therapy |
| US4396625A (en) * | 1980-05-13 | 1983-08-02 | Sumitomo Chemical Company, Limited | Treatment of glaucoma or ocular hypertension and ophthalmic composition |
| US4425346A (en) * | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
| US4304765A (en) | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| JPS58126435U (ja) * | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ｔｔｌオ−トストロボ用絞り制御回路 |
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| DE3220156C2 (de) * | 1982-05-28 | 1990-01-25 | Heida Houston Tex. Thurlow | Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel |
| US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US4478818A (en) * | 1982-12-27 | 1984-10-23 | Alza Corporation | Ocular preparation housing steroid in two different therapeutic forms |
| US4693885A (en) * | 1984-07-18 | 1987-09-15 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| US4675338A (en) * | 1984-07-18 | 1987-06-23 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| FR2577509B1 (fr) | 1985-02-21 | 1987-05-07 | Nirvana Espar Systems Sa | Mat de bateau a voile |
| US4656186A (en) * | 1985-04-30 | 1987-04-07 | Nippon Petrochemicals Co., Ltd. | Tetrapyrrole therapeutic agents |
| US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| FR2594438B1 (fr) * | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
| US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4863457A (en) * | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US4981871A (en) * | 1987-05-15 | 1991-01-01 | Abelson Mark B | Treatment of ocular hypertension with class I calcium channel blocking agents |
| DE3734223A1 (de) | 1987-10-09 | 1989-04-20 | Boehringer Ingelheim Kg | Implantierbares, biologisch abbaubares wirkstofffreigabesystem |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4865846A (en) * | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
| US4968715A (en) | 1988-07-06 | 1990-11-06 | Health Research, Inc. | Use of purified hematoporphyrin trimers in photodynamic therapy |
| US5190966A (en) * | 1988-07-06 | 1993-03-02 | Health Research, Inc. | Purified hematoporphyrin dimers and trimers useful in photodynamic therapy |
| US5198460A (en) * | 1988-07-20 | 1993-03-30 | Health Research Inc. | Pyropheophorbides and their use in photodynamic therapy |
| US5093349A (en) * | 1988-07-20 | 1992-03-03 | Health Research Inc. | Photosensitizing agents |
| US5002962A (en) * | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
| ES2213504T1 (es) | 1988-09-06 | 2004-09-01 | Pfizer Health Ab | Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular. |
| US5595945A (en) * | 1989-01-05 | 1997-01-21 | The United States Of America As Represented By The Department Of Energy | Ceramic composite coating |
| US4935498A (en) * | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5173504A (en) | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5171741A (en) | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US5034413A (en) * | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5268178A (en) | 1989-09-25 | 1993-12-07 | The Board Of Regents, The University Of Texas System | Biodegradable antibiotic implants and methods of their use in treating and preventing infections |
| US5503721A (en) * | 1991-07-18 | 1996-04-02 | Hri Research, Inc. | Method for photoactivation |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5075115A (en) | 1990-04-02 | 1991-12-24 | Fmc Corporation | Process for polymerizing poly(lactic acid) |
| US5232844A (en) * | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
| US5100431A (en) * | 1990-09-27 | 1992-03-31 | Allergan, Inc. | Single stitch suture needle and method |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| JP3351525B2 (ja) * | 1991-06-21 | 2002-11-25 | ジェネティックス・インスティテュート・インコーポレイテッド | 骨形成性蛋白医薬処方物 |
| US5356629A (en) * | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
| US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| US5543154A (en) * | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
| US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| IT1263116B (it) | 1992-04-09 | 1996-07-30 | Rotta Research Lab | Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico |
| US5655832A (en) * | 1992-04-16 | 1997-08-12 | Tir Technologies, Inc. | Multiple wavelength light processor |
| US5244914A (en) * | 1992-04-27 | 1993-09-14 | American Cyanamid Company | Stable porfimer sodium compositions and methods for their manufacture |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US6217869B1 (en) * | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
| US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| WO1995003807A1 (en) * | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
| DE4403326C1 (de) * | 1994-02-03 | 1995-06-22 | Hans Reinhard Prof Dr Koch | Intraokulare Linsenanordnung zur Astigmatismuskorrektur |
| US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| US6270492B1 (en) * | 1994-09-09 | 2001-08-07 | Cardiofocus, Inc. | Phototherapeutic apparatus with diffusive tip assembly |
| AU3533395A (en) | 1994-09-30 | 1996-04-26 | Takeda Chemical Industries Ltd. | Oral sustained-release preparation |
| JPH08151322A (ja) * | 1994-09-30 | 1996-06-11 | Takeda Chem Ind Ltd | 経口徐放剤 |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5906920A (en) * | 1995-08-29 | 1999-05-25 | The Salk Institute For Biological Studies | Methods for the detection of ligands for retinoid X receptors |
| US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US5958954A (en) * | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5877207A (en) * | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| AU2066797A (en) * | 1996-03-21 | 1997-10-10 | Sugen, Inc. | Assays for kdr/flk-1 receptor tyrosine kinase inhibitors |
| US6066675A (en) * | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| US5913884A (en) * | 1996-09-19 | 1999-06-22 | The General Hospital Corporation | Inhibition of fibrosis by photodynamic therapy |
| US6270749B1 (en) * | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
| US6274614B1 (en) * | 1997-02-11 | 2001-08-14 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
| US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| EP0994709A4 (en) * | 1997-06-30 | 2006-02-01 | Allergan Inc | CALCIUM BLOCKER FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY |
| CA2300154C (en) * | 1997-08-11 | 2008-07-08 | Allergan Sales, Inc. | Sterile bioerodible implant device with improved biocompatability and method |
| US6306426B1 (en) * | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
| US6271220B1 (en) * | 1998-03-11 | 2001-08-07 | Allergan Sales, Inc. | Anti-angiogenic agents |
| US5919813C1 (en) * | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
| JP2002506028A (ja) * | 1998-03-13 | 2002-02-26 | ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン | 糖尿病性網膜症または眼炎症の処置におけるゲニステインのようなタンパク質チロシンインヒビターの使用 |
| DE69940738D1 (de) | 1998-07-09 | 2009-05-28 | Curelight Medical Ltd | Vorrichtung und verfahren zur wirkungsvollen hochenergetischen photodynamischen therapie von akne vulgaris und seborrhoe |
| EP1131114B1 (en) | 1998-11-20 | 2004-06-16 | The University of Connecticut | Apparatus and method for control of tissue/implant interactions |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6482854B1 (en) | 1999-03-25 | 2002-11-19 | Massachusetts Eye And Ear Infirmary | Glaucoma treatment |
| EP1178791A2 (en) * | 1999-05-07 | 2002-02-13 | Johns Hopkins University School of Medicine | The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders |
| US6290713B1 (en) * | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
| US6317616B1 (en) | 1999-09-15 | 2001-11-13 | Neil David Glossop | Method and system to facilitate image guided surgery |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6319273B1 (en) | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| CA2398901C (en) | 2000-02-10 | 2010-11-16 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US6357568B1 (en) * | 2000-09-27 | 2002-03-19 | Shou Mao Chen | Structure for protecting a luggage shell |
| AU2002248284A1 (en) | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| AU3649502A (en) | 2000-11-29 | 2002-06-11 | Oculex Pharm Inc | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| US6595945B2 (en) | 2001-01-09 | 2003-07-22 | J. David Brown | Glaucoma treatment device and method |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| CA2443937A1 (en) * | 2001-04-23 | 2002-10-31 | Randall D. Glickman | Prostanoids augment ocular drug penetration |
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| US6713268B2 (en) | 2001-06-26 | 2004-03-30 | Allergan, Inc. | Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7005444B2 (en) | 2001-09-27 | 2006-02-28 | Allergan, Inc. | 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| AU2002341881B2 (en) * | 2001-09-27 | 2008-05-08 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| US20030119812A1 (en) * | 2001-11-08 | 2003-06-26 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
| US20030180294A1 (en) * | 2002-02-22 | 2003-09-25 | Devries Gerald W. | Methods of extending corneal graft survival |
| US6541504B1 (en) | 2002-04-03 | 2003-04-01 | Allergan Sales, Llc | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| AU2003228427B2 (en) * | 2002-04-03 | 2009-07-02 | Allergan, Inc. | (3Z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| US6699863B1 (en) | 2002-11-27 | 2004-03-02 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
| US6747025B1 (en) | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
| US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| US20050003007A1 (en) | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
| US20050009910A1 (en) | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| AU2006295305B2 (en) | 2005-09-16 | 2013-01-31 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| CA2669704A1 (en) | 2006-11-16 | 2008-05-22 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
-
2004
- 2004-04-30 US US10/837,361 patent/US7771742B2/en active Active
-
2005
- 2005-04-27 CA CA2565182A patent/CA2565182C/en active Active
- 2005-04-27 AU AU2005244780A patent/AU2005244780B2/en active Active
- 2005-04-27 WO PCT/US2005/014649 patent/WO2005107706A2/en active Application Filing
- 2005-04-27 CA CA2838526A patent/CA2838526C/en active Active
- 2005-04-27 BR BRPI0509461-5A patent/BRPI0509461A/pt not_active Application Discontinuation
- 2005-04-27 JP JP2007511016A patent/JP2007535556A/ja active Pending
- 2005-04-27 WO PCT/US2005/014811 patent/WO2005112884A1/en not_active Application Discontinuation
- 2005-04-27 EP EP05742156.2A patent/EP1742610B1/en active Active
- 2005-04-29 US US11/119,463 patent/US8481069B2/en active Active
- 2005-04-29 JP JP2007511075A patent/JP5582680B2/ja active Active
- 2005-04-29 AU AU2005240093A patent/AU2005240093B2/en active Active
- 2005-04-29 EP EP05742243A patent/EP1750665B1/en active Active
-
2008
- 2008-02-11 US US12/029,424 patent/US8404267B2/en active Active
- 2008-02-11 US US12/029,425 patent/US8409607B2/en active Active
-
2011
- 2011-08-18 JP JP2011178804A patent/JP5608138B2/ja active Active
-
2012
- 2012-01-11 JP JP2012003321A patent/JP5586637B2/ja active Active
- 2012-06-19 US US13/527,344 patent/US8465778B2/en not_active Expired - Lifetime
-
2013
- 2013-02-26 US US13/777,411 patent/US8968766B2/en not_active Expired - Lifetime
- 2013-07-08 US US13/936,353 patent/US9056045B2/en not_active Expired - Lifetime
-
2014
- 2014-06-03 JP JP2014114968A patent/JP5985536B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014156496A5 (ja) | 生分解性眼内インプラント | |
| Manoukian et al. | Biodegradable polymeric injectable implants for long‐term delivery of contraceptive drugs | |
| RU2015134774A (ru) | Имплантат для пролонгированной доставки лекарственного средства | |
| PH12017501097A1 (en) | Sunitinib formulations and methods for use thereof in treatment of ocular disorders | |
| JP2007535564A5 (ja) | ||
| WO2016042163A3 (en) | Ophthalmic drug compositions | |
| JP2018536484A5 (ja) | ||
| Mohtashami et al. | Pharmaceutical implants: Classification, limitations and therapeutic applications | |
| JP2009501798A5 (ja) | ||
| HRP20220922T1 (hr) | Usadive tablete naltreksona | |
| AR064078A1 (es) | Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion | |
| JP2012521997A5 (ja) | ||
| Bhusal et al. | Controlled release drug delivery systems to improve post-operative pharmacotherapy | |
| JP2013543874A5 (ja) | ||
| BR112015022161A2 (pt) | implante intraocular contendo prostamida | |
| MX359119B (es) | Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas. | |
| JP6568513B2 (ja) | シリコン系担体粒子を含む薬物送達デバイス | |
| Tamaddon et al. | Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis | |
| MX2016001607A (es) | Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas. | |
| JP2011508791A5 (ja) | ||
| JP2016538292A5 (ja) | ||
| ATE439877T1 (de) | Gerollter draht zur kontrollierten freisetzung von arzneimitteln an das auge | |
| BR112015011294A8 (pt) | nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas | |
| RU2016119132A (ru) | Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества | |
| Shukla et al. | Chitosan as a biomaterial for implantable drug delivery |